Lymphoma, Low-Grade Completed Phase 2 Trials for Ibritumomab tiuxetan (DB00078)

Also known as: Low-Grade Lymphoma

IndicationStatusPhase
DBCOND0029914 (Lymphoma, Low-Grade)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00220285Study for Evaluation of Efficacy and Safety of SH L 749 to Indolent B-cell Non-Hodgkin's LymphomaTreatment